As new deep pockets emerge to finance psychedelic drug development, we also learn that this R&D isn’t as expensive as some drug companies claim.

Red Light Holland partner, CCrest Laboratories, has been approved by a Health Canada as a supplier of psilocybin for the SAP.

Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.

atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.

Novamind announces the closing of its previously announced CAD$5 million private placement.

MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.

Awakn files a patent application in support of a new class of molecules for the treatment of addiction.

Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.

Mydecine announces a partnership with Combat Stress and King’s College London to provide psychoactive-assisted therapy for PTSD.

Mindmed receives IND clearance from the FDA for MM-120, paving the way for its Phase IIb clinical trial for generalized anxiety disorder.